載入中
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
收盤時
US$3.51
+US$0.12 · +3.54%
盤後
US$3.57
+US$0.06 · +1.71%
10月12日 下午7:59 ET
盤中時間採用ET。市場資料可能有所延遲。
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
日內區間
目前US$3.51
52週區間
目前US$3.51
盤中時間採用ET。市場資料可能有所延遲。
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
日內區間
目前US$3.51
52週區間
目前US$3.51
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 74.46萬 USD | 4617.55萬 USD | 5480.7萬 USD | 1.13億 USD | 9062.16萬 USD |
| 銷售、一般及管理費用 | 31.19萬 USD | 3771.55萬 USD | 4889.5萬 USD | 4792.61萬 USD | 3508.19萬 USD |
| 營業費用 | 5910.02萬 USD | 8389.1萬 USD | 1.04億 USD | 1.61億 USD | 1.26億 USD |
| 利息收入 | 139.6萬 USD | 353萬 USD | 515.17萬 USD | 265.9萬 USD | 119.91萬 USD |
| 折舊和攤銷 | — | — | 1.04億 USD | 2000 USD | 1258 USD |
| 營業利益 | −5910.02萬 USD | −8389.1萬 USD | −1.04億 USD | −1.61億 USD | −1.26億 USD |
| 淨利 | −5738.52萬 USD | −7997.94萬 USD | −9879.2萬 USD | −1.57億 USD | −1.26億 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$12.00
上漲空間 241.88%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2019年9月30日 | 1:4 | — | — |
股票分割 | 2015年8月12日 | 1:5 | — | — |
已生效 2019年9月30日
1:4
已生效 2015年8月12日
1:5
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1382.03萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM836.71萬0.01%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF530.9萬0.01%954億 USD0.05%US$233.52-0.63%
State Street SPDR S&P Pharmaceuticals ETFXPH394.64萬0.85%4.69億 USD0.35%US$64.01-0.99%
iShares Russell 2000 Growth ETFIWO292.29萬0.02%139.17億 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO236.71萬0.01%180億 USD0.06%US$112.27-0.35%
AdvisorShares Psychedelics ETFPSIL211.26萬4.51%4574.2萬 USD1.84%US$21.26-2.32%
Vanguard Health Care ETFVHT107.92萬0.00%220億 USD0.09%US$320.67+0.52%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAdvisorShares Psychedelics ETFPSILVanguard Health Care ETFVHTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
